[1]Bonis PA, Friedman SL, Kaplan MM.Is liver fibrosis reversible?[J].N Engl J Med, 2001, 344 (6) :452-454.
|
[2]Friedman SL.Mechanisms of hepatic fibrogenesis[J].Gastroenter-ology, 2008, 134 (6) :1655-1669.
|
[3]Novo E, Parola M.Redox mechanisms in hepatic chronic wound healingand fibrogenesis[J].Fibrogenesis Tissue Repair, 2008, 1 (1) :5.
|
[4]Borkham-Kamphorst E, Claudia RC, van Roeyen CR, et al.Pro-fibrogenic potential of PDGF-D in liver fibrosis[J].J Hepatol, 2007, 46 (6) :1064-1074.
|
[5]Zhou K, Gao CF, Zhao YP, et al.Simpler score of routine labora-tory tests predicts liver fibrosis in patients with chronic hepatitis B[J].J Gastroenterol Hepatol, 2010, 25 (9) :1569-1577.
|
[6]Gressner OA, Weiskirchen R, Gressner AM.Biomarkers of liver fi-brosis:clinical translation of molecular pathogenesis or based on liv-er-dependent malfunction tests[J].Clin Chim Acta, 2007, 381 (2) :107-113.
|
[7]Giannini E, Caglieris S, Ceppa P, et al.Serum pro-collagen IIIpeptide levels are related to lobular necrosis in untreated patientswith chronic hepatitis C[J].Eur Gastroenterol Hepatol, 2001, 13 (2) :137-141.
|
[8]Degott C, Zafrani ES, Callard P, et al.Histopathological study of pri-mary biliary cirrhosis and the effect of ursodeoxycholic acid treatment onhistology progression[J].Hepatology, 1999, 29 (4) :1007-1012.
|
[9]George DK, Ramm GA, Walker NI, et al.Elevated serum type IVcollagen:a sensitive indicator of the presence of cirrhosis in haemo-chromaosis[J].J Hepatol, 1999, 31 (1) :47-52
|
[10]Murawaki Y, Ikuta Y, Okamoto K, et al.Diagnostic value of serummarkers of connective tissue turnover for predicting histological stag-ing and grading in patients with chronic hepatitis C[J].J Gastroen-terol, 2001, 36 (6) :399-406.
|
[11]Saitou Y, Shiraki K, Yamanaka Y, et al.Noninvasive estimation ofliver fibrosis and response to interferon therapy by a serum fibrogen-esis marker, YKL-40, in patients with HCV-associated liver dis-ease[J].World J Gastroenterol, 2005, 11 (4) :476-481.
|
[12]Johansen JS.Studies on serumYKL-40 as a biomarker in diseaseswith inflammation, tissue remodelling, fibroses and cancer[J].DanMed Bull, 2006, 53 (2) :172-209.
|
[13] Walsh KM, Timms P, Campbell S, et al.Plasma levels of matrixmetalloproteinase-2 (MMP-2) and tissue inhibitors of metallo-proteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasivemarkers of liver disease in chronic hepatitis C:comparison usingROC analysis[J].Dig Dis Sci, 1999, 44 (3) :624-630.
|
[14]Quan TE, Cowper S, Wu SP, et al.Circulating fibrocytes:collagen-secreting cells of the peripheral blood[J].Int J Biochem Bio, 2004, 36 (4) :598-606.
|
[15]Gressner OA, Gressner AM.Connective tissue growth factor:a fi-brogenic master switch in fibrotic liver diseases[J].Liver Int, 2008, 28 (8) :1065-1079.
|
[16]Tacke F, Gabele E, Bataille F, et al.Bone morphogenetic protein7 is elevated in patients with chronic liver disease and exerts fibro-genic effects on human hepatic stellate cells[J].Dig Dis Sci, 2007, 52 (12) :3404-3415.
|
[17]Camps J, Marsillach J, Joven J.Measurement of serum paraoxonase-1 activity as a potential biomarker for chronic liver impairment[J].Clin Chim Acta, 2007, 386 (1-2) :114-115.
|
[18]Kuhn J, Gressner OA, Gotting C, et al.Increased serum xylosyl-transferase activity in patients with liver fibrosis[J].Clin Chim Ac-ta, 2009, 409 (1-2) :123-126.
|
[19]Schttler M, Müller S, Schn S, et al.Serum xylosyltransferase Iactivity, the new biochemical fibrosis marker, is not affected by renalinsufficiency[J].Clin Biochem, 2005, 38 (5) :486-488.
|
[20]Poon TC, Hui AY, Chan HL, et al.Prediction of l iver fibrosis andcirrhosis in chronic hepatitis B infection by serum proteomic F Inger-printing:a pilot study[J].Clin Chem, 2005, 51 (2) :328-335.
|
[21]Callewaert N, VLierberghe HV, Hecke AV, et al.Noninvasive diag-nosis of liver cirrhosis using DNA sequencer-based total serum pro-tein glycomics[J].Nat Med, 2004, 10 (4) :429-434.
|
[22]Zeng MD, Lu LG, Mao YM, et al.Prediction of significant Fibrosisin HBeAg-Positive Patients with Chronic Hepatitis B by a Noninva-sive Modelogy[J].Hepatology, 2005, 42 (6) :1437-1445.
|
[23]Franzini M, Corti A, Fornaciari I, et al.Cultured human cells re-lease soluble gamma-glutamyltransferase complexes correspondingto the plasma b-GGT[J].Biomarkers, 2009, 14 (7) :486-492.
|
[24]Shaheen AA, Myers RP.Diagnostic accuracy of the aspartate amin-otransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis:a systematic review[J].Hepatology, 2007, 46 (3) :912-921.
|
[25]Jacqueminet S, Lebray P, Morra R, et al.Screening for liver fibro-sis by using a noninvasive biomarker in patients with diabetes[J].Clin Gastroenterol Hepatol, 2008, 6 (7) :828-831.
|
[26]Poynard T, Ngo Y, Marcellin P, et al.Impact of adefovir dipivoxilon liver fibrosis and activity assessed with biochemical markers (Fi-broTest-ActiTest) in patients infected by hepatitis B virus[J].JViral Hepat, 2009, 16 (3) :203-213.
|
[27]Castera L.Transient elastography and other noninvasive tests to as-sess hepatic fibrosis in patients with viral hepatitis[J].J Viral Hep-at, 2009, 16 (5) :300-314.
|